Doravirine (HIV infection in adolescents) – Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Doravirine (HIV infection in adolescents) – Benefit assessment according to §35a Social Code Book V

   published on

   01.08.2022

   Document type

   PDF-Dokument, 365 kB, EN, PDF

   Download file : Extract of dossier assessment (PDF-Dokument, 365 kB, EN, PDF)
2. Dossier assessment

   Doravirine (HIV infection in adolescents) – Benefit assessment according to §35a Social Code Book V

   published on

   01.08.2022

   Document type

   PDF-Dokument, 508 kB, DE, PDF

   Download file : Dossier assessment (PDF-Dokument, 508 kB, DE, PDF)

Dossier assessment

Project details

Project no.

A22-52

Commission

Commission awarded on 02.05.2022 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Immune system and infections

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

1. Dossier assessment

   Doravirine (HIV infection) - Benefit assessment according to §35a Social Code Book V

   Project no.

   A19-07

   Last updated

   15.04.2019

   Status: Commission completed